Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
EVAX | US
0.18
5.07%
Healthcare
Biotechnology
30/06/2024
08/06/2026
3.73
3.70
3.77
3.70
Evaxion Biotech A/S a clinical-stage biotech company engages in developing artificial intelligence-powered immunotherapies for cancers bacterial diseases and viral infections. The company develops EVX-01 a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02 a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03 a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1 EVX-B2 and EVX-V1 which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm Denmark.
View LessLow Market Beta (-0.4 to 0.8)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
81.4%1 month
62.6%3 months
71.7%6 months
85.4%-
3.57
12.06
8.37
0.69
-0.59
63.35
-
-18.80M
20.81M
20.81M
-
-2.97K
-
-
-802.80
0.90
2.14
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.81
Range1M
1.08
Range3M
1.72
Rel. volume
0.63
Price X volume
75.69K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| India Globalization Capital Inc | IGC | Drug Manufacturers-Specialty & Generic | 0.299 | 22.62M | 4.55% | n/a | 4.33% |
| Reviva Pharmaceuticals Holdings Inc. | RVPH | Biotechnology | 0.669 | 22.14M | -6.43% | n/a | 0.00% |
| Indaptus Therapeutics Inc. Common Stock | INDP | Biotechnology | 2.1 | 21.41M | -42.62% | n/a | 2.12% |
| RenovoRx Inc. Common Stock | RNXT | Biotechnology | 0.8856 | 21.24M | 1.56% | n/a | 0.00% |
| Dyadic International Inc | DYAI | Biotechnology | 0.699 | 20.60M | -1.63% | n/a | 175.64% |
| InMed Pharmaceuticals Inc | INM | Biotechnology | 1.54 | 20.54M | -2.53% | n/a | 7.00% |
| DOMH | DOMH | Biotechnology | 3.17 | 19.90M | 2.26% | n/a | 7.66% |
| Can-Fite BioPharma Ltd | CANF | Biotechnology | 3.08 | 18.78M | -0.32% | n/a | 0.00% |
| QNRX | QNRX | Biotechnology | 4.57 | 18.19M | 1.78% | n/a | 43.11% |
| CELU | CELU | Biotechnology | 0.812 | 17.85M | -6.91% | n/a | 127.38% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.1 | 16.07M | 7.84% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.4131 | 7.98M | -3.48% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.49 | 3.81M | 12.88% | n/a | 17.32% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0058 | 534.84K | n/a | -37.05% | |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4181 | 230.37K | 7.87% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.59 | 0.53 | Cheaper |
| Ent. to Revenue | 63.35 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 12.06 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 71.71 | 72.80 | Par |
| Debt to Equity | 8.37 | -1.23 | Expensive |
| Debt to Assets | 0.69 | 0.25 | Expensive |
| Market Cap | 20.81M | 3.66B | Emerging |